This will likely not be an impediment to treatments based on CRISPR. The study has been available in preprint form for ~6 months on biorxiv [0]. At least some of the companies researching CRISPR were aware of this issue at the time the paper was released. It has since been mitigated, as specified at the bottom of the article. From Gaetan Burgio's tweets:
"Published now in @NatureMedicine on #CRISPR & Immunity to SpCas9. 6 months has past since the preprint was online & it is a long time in the CRISPR field. Since then additional work showed how to circumvented this by modifying Cas9 protein or using Cas9 orthologs. So No panic !" [1]
[0] https://www.biorxiv.org/content/early/2018/04/04/295139
[1] https://twitter.com/GaetanBurgio/status/1057206850213441542